Institute of Cancer Research UK has identified proteolysis targeting chimeras (PROTACs) comprising a Von Hippel-Lindau disease tumor suppressor (VHL) binding moiety coupled to a receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) targeting moiety via a linker.
Hainan Simcere Pharmaceutical Co. Ltd. has synthesized protein degradation inducers comprising a regulator and/or promoter of protein proteasomal degradation moiety covalently linked to a protein targeting moiety through a linker reported to be useful for the treatment of cancer.
Gilead Sciences Inc. has disclosed protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Glenmark Pharmaceuticals Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated kinase 3 (IRAK-3; IRAK-M) targeting moiety via linker reported to be useful for the treatment of cancer.
Bial-Portela & Ca SA has identified orexin OX1 receptor antagonists reported to be useful for the treatment of cognitive, sleep, anxiety and eating disorders, depression, obesity, schizophrenia, substance abuse and dependence, among others.
2A Biosciences Inc. has synthesized tryptamine derivatives acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric, neurodegenerative, neurodevelopmental, inflammatory and eye disorders.
Fudan University has disclosed phosphatidylcholine:ceramide cholinephosphotransferase 2 (SGMS2; SMS2) inhibitors reported to be useful for the treatment of cancer, atherosclerosis, dry eye, pulmonary edema, fatty liver, obesity, type 2 diabetes and Alzheimer’s disease.
The U.S. Court of Appeals for the Federal Circuit occasionally remands a patent litigation case to district court for a variety of reasons, as seen in a decision involving Trudell Medical and D R Burton.
Bsense Bio Therapeutics Ltd. has disclosed new potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators and transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonists reported to be useful for the treatment of neuropathic pain, pruritus and tinnitus.
RSS
